Revolution Medicines Reiterates FY 2026 Operating Expense Guidance

Revolution Medicines reported a net loss of $407.5 million for the third quarter of 2026, compared to a net loss of $305.2 million in the same period of 2025. The company reiterated its full-year 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion. Management highlighted the U.S. approval and launch of RASONQUE (daraxonrasib) as a transformational milestone for the company. Additionally, the company provided updates on its clinical pipeline, including progress in the RASolute 303, 304, and 305 trials, and the ongoing development of RMC-5127.